

GENERAL INFORMATION

G P F M

Kjelsåsveien 168 B
0884 Oslo
Norway

Contact Person Ms. Tone Kvåle, CFO
Phone + 47 (22) 183301
Fax + 47 (22) 580007
Email mail@nordicnanovector.com
Website www.nordicnanovector.com

Founded in 2009
Source of foundation Independent foundation

Corporate description / mission

Nordic Nanovector is focusing on the development and commercialization of novel targeted therapeutics for haematological cancers. The company's lead clinical-stage product is Betalutin®, a antibody radionuclide conjugates (ARCs), designed to improve upon and complement current options for the treatment of non-Hodgkin lymphoma (NHL).

Headquarters Yes

Primary stock exchange OMX Oslo (OSE) (NANO.OL)

IPO in (year) 2015

Remarks

Nordic Nanovector was established in Oslo, Norway in 2009 by Dr Roy H. Larsen and Inven2 AS on behalf of Professor Øyvind S. Bruland and Dr Jostein Dahle.

Formerly known as Nordic Nanovector AS.

CATEGORIZATION

G P F M

Main sector Biotechnology - Therapeutics and Diagnostics

Business Model . R&D

Sub sector . Other
. Antibodies

Customer Segments . Large biotech & big pharma
. Small biotech
. Physicians / doctors
. Hospitals

Primary therapeutic area(s) . Neoplasms / cancer / oncology

SUMMARY PRODUCTS / SERVICES / TECHNOLOGIES

G P F M

No. of Biotech Products **Pre-clinical** **Phase I**
1 3

Description of products

Betalutin
NNV009
NNV011
NNV013. etc

FINANCIALS (All figures in millions (except <<No. of sh..

G P F M

Financing details

Market Cap as on 2 June 18.

Fiscal year (end of) 2017

Revenues	USD	0.30
Cash	USD	756 57

COLLABORATION AND CLIENTS

G P F M

Partnering strategy / collaborations

INSERM

- Dana Farber
- Paul Scherrer Institute
- Heidelberg Pharma
- LegoChemBio
- ArevaMed
- IOR cancer institute
- Norwegian Radium Hospital
- University of Bergen
- UMCG

PIPELINE OF BIOTECH PRODUCTS

G P F M

entered Biotech products 8

	Discovery	Lead opt	Prec.	Ph. I	Ph. II	Ph. III	NDA	on the Market
LYMRIT-37-01								
LYMRIT-37-02								
LYMRIT-37-05								
NNV009 for..								
NNV011								
NNV013								
NNV014								
NNV019								

BIOTECH PRODUCTS OF NORDIC NANOVECTOR ASA

G P F M

Biotech products 8

LYMRIT-37-01

Biotech product 1/8

A Phase 1/2 Study of Betalutin® for treatment of relapsed indolent Non-Hodgkin lymphoma.

Licensing status	Undisclosed	Main Indication	Neoplasms / cancer / oncology
Development phase	Phase I	Sub Indication	Non-Hodgkin's lymphoma

LYMRIT-37-02

Biotech product 2/8

Phase 1, open label, randomized study to assess pharmacokinetics, biodistribution and dosimetry of Betalutin® in patients with relapsed Non-Hodgkin lymphoma.

Development phase	Phase I	Main Indication	Neoplasms / cancer / oncology
		Sub Indication	Non-Hodgkin's lymphoma

LYMRIT-37-05

Biotech product 3/8

Phase 1, open-label, dose finding study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Development phase	Phase I	Main Indication	Neoplasms / cancer / oncology
-------------------	---------	-----------------	-------------------------------

NNV009 for NHL

Biotech product 4/8

Licensing status	Partnered	Main Indication	Neoplasms / cancer / oncology
Development phase	Preclinical	Sub Indication	Non-Hodgkin's lymphoma

Partners

University Medical Center Groningen

NNV011

Biotech product 5/8

NNV011 is being developed for the treatment of Leukaemia.

Licensing status Partnered

Development phase Discovery

Main Indication Neoplasms / cancer / oncology

Sub Indication Leukaemia - others

Partners

Paul Scherrer Institute

NNV013

Biotech product 6/8

NNV013 is being developed for the treatment of Leukaemia.

Licensing status Partnered

Development phase Discovery

Main Indication Neoplasms / cancer / oncology

Sub Indication Leukaemia - others

Partners

ArevaMed

NNV014

Biotech product 7/8

NNV014 is being developed for the treatment of Leukaemia.

Licensing status Partnered

Development phase Discovery

Main Indication Neoplasms / cancer / oncology

Partners

Heidelberg Pharma

NNV019

Biotech product 8/8

NNV019 is being developed for the treatment of Leukaemia.

Licensing status Partnered

Development phase Discovery

Main Indication Neoplasms / cancer / oncology

Sub Indication Leukaemia - others

Partners

LegoChem Bio

FINANCING ROUNDS

G P **F** M

rounds **9**

Dec 2016

round **1/9**

Type of round / series private placement

Financing stage / type of financing Post-IPO

Phase of most advanced

Biotech product Phase II

Investment (in millions) NOK 498.70

Remarks/Milestones

Nordic Nanovector intends to use the net proceeds of the Private Placement:

- To fund a Phase 2 combination study of Betalutin® and Rituximab CD20
- To fund a Phase 1 study and GMP manufacturing for 177Lu-conjugated chimeric antibody (anti-CD37 ARC)
- Develop new proprietary antibody production technology
- Accelerate pipeline of pre-clinical assets to clinical trials
- Prepare for commercial launch of Betalutin®
- General corporate purposes.

Feb 2016

round **2/9**

Financing stage / type of financing Research grants

Investment (in millions) NOK 15.00

Lead investor

Research Council of Norway's User-driven Research-based Innovation programme

Remarks/Milestones

This grant funding enables to advance early stage research that leverages their expertise in ARC therapies, particularly around CD37-targeted approaches, as a means of developing a broader portfolio of products behind Betalutin® for treating malignant leukaemias and lymphomas.

Mar 2015

round **3/9**

Financing stage / type of financing IPO

Investment (in millions) NOK 500.00

Remarks/Milestones

Nordic Nanovector expects to begin a pivotal Phase II trial in mid-2015 of lead candidate Betalutin, a lutetium-177 radiopharmaceutical conjugated to an anti-CD37 mAb to treat follicular lymphoma. It expects preliminary results in 2H16. Betalutin also is in a Phase I/II trial to treat non-Hodgkin's lymphoma (NHL).

Jun 2014

round **4/9**

Type of round / series Private placement

Financing stage / type of financing Other

Investment (in millions) NOK 250.00

Co-investors

Existing shareholders as well and new institutional and professional investors. The Company's largest shareholder, HealthCap VI L.P. participated in the placement and were allocated 1,800,000 shares.

Remarks/Milestones

The Company intends to use the net proceeds of the Private Placement to fund further clinical development of Betalutin™ for treatment of non-Hodgkin Lymphoma.

May 2014

round **5/9**

Financing stage / type of financing Convertible loan

Investment (in millions)	NOK	25.00
--------------------------	-----	-------

Sep 2013

round 6/9

Type of round / series Private placement

Investment (in millions)

NOK

50.00

Financing stage / type of financing Other

Lead investor

HealthCap VI L.P.

Remarks/Milestones

The company intends to use the majority of the net proceeds to fund R&D activities for its lead product candidate Betalutin™, including the funding of two planned Phase II clinical trials.

Jun 2013

round 7/9

Financing stage / type of financing Equity (private)

Investment (in millions)

NOK

60.00

Remarks/Milestones

The funding will enable the company to accelerate the clinical development of their lead product-candidate Betalutin™ as well as to advance a preclinical product- candidate into a clinical setting.

Apr 2013

round 8/9

Financing stage / type of financing Convertible loan

Investment (in millions)

NOK

4.00

Jan 2012

round 9/9

Type of round / series Private Placement

Investment (in millions)

NOK

14.30

Remarks/Milestones

Proceeds from the emission will be used for further development of Nordic Nanovector's lead product candidate, Betalutin™ and the company's discovery pipeline.

MANAGEMENT		G	P	F	M	persons	10
Mr. Bravo Eduardo	Chief Executive Officer						
Ms. Brondberg Malene	Vice President, Investor Relations and Corporate Communications						
Ms. Corrigan Rosemarie	Chief Quality Officer						
Dr. Dahle Jostein	Chief Scientific Officer (CSO)						
Dr. Deehan Maureen	Head of Corporate Development and Strategy						
Ms. Dege Rita	Chief Human Resources Officer (CHRO)						
Ms. Hagen Anniken	Chief Technical and Operations Officer						
Ms. Kvåle Tone	Chief Financial Officer						
Dr. Renoldi Marco	Chief Operating Officer (COO)						
Dr. Rojkjaer Lisa	Chief Medical Officer (CMO)						
BOARD OF DIRECTORS		G	P	F	M	persons	7
Dr. Boehm Rainer	Director						
Ms. Hermansen Steineger Hilde	Board Member						
Ms. Horobin Joanna	Board Member						
Dr. Pierre Bizzari Jean	Board Member						
Mr. Samuelsson Per	Board Member						
Mr. Sandnes Ludvik	Chairman of the Board						
Ms. Schwab Gisela	Board Member						
ADVISORY BOARD		G	P	F	M	persons	11
Prof. Caballero Dolores	Scientific Advisor						
Dr. D'Amore Francesco	Scientific Advisor						
Prof. Illidge Timothy	Chair						
Prof. Jurczak Wojciech	Board member						
Dr. Kaminski Mark	Scientific Advisor						
Dr. Kolstad Arne	Scientific Advisor						
Prof. Lopez-Guillermo Armando	Board member						
Dr. Morschhauser Franck	Scientific Advisor						
Prof. Schuster Stephen	Scientific Advisor						
Prof. Trümper Lorenz	Scientific Advisor						
Prof. Zinzani Pierluigi	Chair						

KEY

G General

P Products

F Financing

M Management